159 related articles for article (PubMed ID: 35645169)
1. The Risk for Prostate Cancer With Calcium Channel Blockers: A Systematic Review, Meta-Analysis, and Meta-Regression.
Rotshild V; Rabkin N; Matok I
Ann Pharmacother; 2023 Jan; 57(1):16-28. PubMed ID: 35645169
[TBL] [Abstract][Full Text] [Related]
2. Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis.
Yang H; Yu Y; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Feng X; Liu L
Clin Ther; 2020 Sep; 42(9):1715-1727.e2. PubMed ID: 32807506
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blockers and the incidence of breast and prostate cancer: A meta-analysis.
Thakur AA; Wang X; Garcia-Betancourt MM; Forse RA
J Clin Pharm Ther; 2018 Aug; 43(4):519-529. PubMed ID: 29656432
[TBL] [Abstract][Full Text] [Related]
5. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.
Rotshild V; Azoulay L; Zarifeh M; Masarwa R; Hirsh-Raccah B; Perlman A; Muszkat M; Matok I
Drug Saf; 2018 Jun; 41(6):555-564. PubMed ID: 29484611
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding.
He Y; Chan EW; Leung WK; Anand S; Wong IC
Aliment Pharmacol Ther; 2015 Jun; 41(12):1246-55. PubMed ID: 25898902
[TBL] [Abstract][Full Text] [Related]
7. Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study.
Rotshild V; Azoulay L; Feldhamer I; Perlman A; Muszkat M; Matok I
Pharmacotherapy; 2019 Jun; 39(6):690-696. PubMed ID: 30917404
[TBL] [Abstract][Full Text] [Related]
8. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers.
Makarounas-Kirchmann K; Glover-Koudounas S; Ferrari P
Clin Ther; 2009 Aug; 31(8):1652-63. PubMed ID: 19808126
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies.
Cao L; Zhang S; Jia CM; He W; Wu LT; Li YQ; Wang W; Li Z; Ma J
BMC Urol; 2018 Mar; 18(1):17. PubMed ID: 29514670
[TBL] [Abstract][Full Text] [Related]
10. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
Rirash F; Tingey PC; Harding SE; Maxwell LJ; Tanjong Ghogomu E; Wells GA; Tugwell P; Pope J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD000467. PubMed ID: 29237099
[TBL] [Abstract][Full Text] [Related]
11. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
[TBL] [Abstract][Full Text] [Related]
12. Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics.
Vouri SM; Jiang X; Manini TM; Solberg LM; Pepine C; Malone DC; Winterstein AG
JAMA Netw Open; 2019 Dec; 2(12):e1918425. PubMed ID: 31880802
[TBL] [Abstract][Full Text] [Related]
13. Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies.
Chen Q; Zhang Q; Zhong F; Guo S; Jin Z; Shi W; Chen C; He J
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):711-8. PubMed ID: 24829113
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis.
Lin Y; Ma L
Medicine (Baltimore); 2018 Nov; 97(48):e13152. PubMed ID: 30508892
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis.
Lang Y; Gong D; Fan Y
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):559-66. PubMed ID: 25845582
[TBL] [Abstract][Full Text] [Related]
16. High-dose calcium channel blocker (CCB) monotherapy vs combination therapy of standard-dose CCBs and angiotensin receptor blockers for hypertension: a meta-analysis.
He T; Liu X; Li Y; Liu XY; Wu QY; Liu ML; Yuan H
J Hum Hypertens; 2017 Feb; 31(2):79-88. PubMed ID: 27511478
[TBL] [Abstract][Full Text] [Related]
17. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies.
Hussain S; Singh A; Rahman SO; Habib A; Najmi AK
Neurosci Lett; 2018 Apr; 671():120-127. PubMed ID: 29452176
[TBL] [Abstract][Full Text] [Related]
18. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
19. Calcium channel blockers and Parkinson's disease: a systematic review and meta-analysis.
Lin J; Pang D; Li C; Ou R; Yu Y; Cui Y; Huang J; Shang H
Ther Adv Neurol Disord; 2024; 17():17562864241252713. PubMed ID: 38770432
[TBL] [Abstract][Full Text] [Related]
20. No Association Between Calcium Channel Blockers and Survival in Patients with Cancer: A Systematic Review and Meta-analysis.
Sun H; Zhuang RY; Li T; Zheng YT; Cai WM
Asian Pac J Cancer Prev; 2016; 17(8):3917-21. PubMed ID: 27644639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
